Pegcetacoplan significantly reduces proteinuria in patients with recurrent C3 glomerulopathy, or primary immune-complex ...

CRESTWOOD, Ky. and WALTHAM Mass., Oct. 11, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq: APLS), a clinical-stage biopharmaceutical company focused on the development of novel ...

The fact that the complement system is activated during immune-complex glomerular disease has been known for nearly 50 years. Detection of complement deposition in the glomerulus using immunochemistry ...

NEEDHAM, Mass.--(BUSINESS WIRE)--Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced key in vivo efficacy data for its CDX-1135 program from a collaboration with Drs. Richard Smith and Carla ...

On Monday, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) released topline results from Part 2 of a Phase 1/2 study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic designed ...

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the first report describing the effects of lectin-pathway inhibition by narsoplimab on urinary complement levels in ...

Here, we describe a patient with an early onset of endocapillary glomerulonephritis and CFH deficiency. Genetic analyses revealed uniparental isodisomy and a novel mutation as the unusual molecular ...

Complement component 3, often called C3, is an essential protein of the immune system. This protein plays a vital role in the body’s innate immune system, providing: the first line of defense against ...

Findings suggest that the complement system plays a role in the onset of acute kidney injury in critically ill patients. Urinary Ba, a fragment of complement factor B, may be a biomarker and mediator ...

An ultra-rare kidney disease that can become life-threatening now has its first FDA-approved therapy. The affirmative regulatory decision is the third for Novartis’s Fabhalta, building up the drug’s ...

PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a clinical trial (NCT06209177) of ARO-CFB, the ...